Fig 1.
Map of the 21 study communities.
Communities were part of a randomized trial set in the Gurage Zone of Ethiopia. The star depicts the capital of the zone, Wolkite. Map boundaries were taken from GADM version 4.0 (https://gadm.org).
Fig 2.
Participant flow is shown separately for baseline (i.e., pre-treatment), month 2, and month 6.
Fig 3.
Concordance of ompA type in 21 Ethiopian communities.
Panel A shows all households in the random sample that had multiple children with ompA results. Each row of boxes represents a unique child’s ompA results over time, from before the mass azithromycin distribution (i.e., month 0) to 6 months post-treatment. Blank spaces represent visits with no specimen collected. Shaded boxes represent those swabs selected for the study, and hence those eligible for ompA sequencing. Shaded boxes are labeled with the sequenced ompA type using the arbitrary naming conventions of this study (i.e., A1, A2, B1, etc.) or with “+” if the ompA type could not be determined. Unshaded boxes are labeled according to the polymerase chain reaction (PCR) results for C. trachomatis as positive (“+”) or negative (“-“). Households are delineated with thick black lines and communities with grey dashed lines. Panel B shows all children experiencing Chlamydia trachomatis re-infection after mass azithromycin treatment (i.e., positive test results at baseline, negative results at month 2, and positive results again at month 6), regardless of whether they were selected for the random sample. Discordant ompA types are shown in red.